Related Experiment Video

Updated: Feb 26, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting

Yoshiko Umeyama1, Yoshiyuki Shibasaki1, Hideyuki Akaza2

  • 1Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan.

Future Oncology (London, England)
|July 15, 2017
PubMed

Insights

Axitinib is a targeted therapy for advanced renal cell carcinoma. Managing side effects and optimizing dosage can help patients stay on treatment longer for better outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced and metastatic renal cell carcinoma (RCC) treatment has evolved with targeted therapies.
  • Axitinib, a VEGFR inhibitor, is a key second-line treatment for advanced RCC.

Purpose of the Study:

  • To summarize factors for effective axitinib administration in advanced RCC.
  • To explore axitinib's potential in various clinical settings beyond second-line treatment.

Main Methods:

  • Review of clinical data and treatment guidelines for axitinib in RCC.
  • Discussion of individualized dosing, adverse event management, and future therapeutic strategies.

Main Results:

  • Individualized dose titration and proactive management of adverse events are crucial for prolonged treatment duration.
  • Axitinib shows promise in first-line, sequential, neoadjuvant/adjuvant settings, and in combination with immunotherapy.

Conclusions:

  • Optimizing axitinib administration can improve patient outcomes in advanced RCC.
  • Further research into axitinib's expanded roles is warranted to enhance efficacy.
Keywords:
axitinibmetastatic renal cell carcinomatargeted therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
684
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
376